Autoimmunity in thrombotic thrombocytopenic purpura

Seminars in Thrombosis and Hemostasis

Volumn 31, Issue 6, 2005, Pages 633-640

  Porta, Camillo ^a,b   Caporali, Roberto ^a   Montecucco, Carlomaurizio ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b Int Medicine and Medical Oncology   (Italy)

Author keywords

ADAMTS13 antibodies; Antiphospholipid syndrome; Immunosuppressants; Rituximab; Thrombotic thrombocytopenic purpura (TTP)

Indexed keywords

ANTITHROMBOCYTIC AGENT; AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; RITUXIMAB; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNITY; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; ENDOTHELIUM LESION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; REVIEW; SPLENECTOMY; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNITY; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOSUPPRESSION; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 30344441119     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-925469     Document Type: Review

References (92)

1. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc NY Pathol Soc 1924;24:21-24
2. Singer K, Bornstein FP, Wile SA. Thrombotic thrombocytopenic purpura. Hemorrhagic diathesis with generalized platelet thromboses. Blood 1947;2:542-544
3. Neame PB. Immunologic and other factors in thrombotic thrombocytopenic purpura (TTP). Semin Thromb Hemost 1980;6:416-429
4. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma-exchange with plasma-infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991;325:393-397
5. Moses J, Lichtman SM, Brody J, Wisch N, Moake JL. Hairy cell leukemia in association with thrombotic thrombocytopenic purpura and factor VIII antibodies. Leuk Lymphoma 1996;22:351-354
6. Tada T, Kishimoto H. An autopsy case of thrombotic thrombocytopenic purpura (TTP) complicated with systemic lupus erythematosus (SLE)-demonstration of anti-platelet antibody. Rinsho Ketsueki 1980;21:1773-1780
7. Bodensteiner D, Rosenfeld C. Elevated platelet-surfacebound IgM in thrombotic thrombocytopenic purpura. South Med J 1988;81:81-83
8. Nakajima T, Koyama T, Kakishita E, Nagai K. Inhibitory effects of TTP sera on binding of anti-platelet glycoprotein IIb-IIIa monoclonal antibodies to human vascular endothelial cells. Am J Hematol 1987;25:115-118
9. Stein RS, Flexner JM. Persistently perplexing purpuras: thrombotic thrombocytopenic purpura and immune throm-bocytopenic purpura. Ann Intern Med 1994;121:720-721 (letter)
10. Leung DY, Moake JL, Havens PL, Kim M, Pober JS. Lytic anti-endothelial cell antibodies in haemolytic-uraemic syndrome. Lancet 1988;23:183-186
11. Koenig DW, Barley-Maloney L, Daniel TO. A Western blot assay detects autoantibodies to cryptic endothelial antigens in thrombotic microangiopathies. J Clin Immunol 1993;13:204-211
12. Tandon NN, Rock G, Jamieson GA. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura. Br J Haematol 1994;88:816-825
13. Porta C, Caporali R, Montecucco C. Thrombotic thrombocytopenic purpura and autoimmunity: a tale of shadows and suspects. Haematologica 1999;84:260-269
14. Gorini M, Luliri P. Steroids: what role in TTP? Transfus Sci 1992;13:73-76
15. Bobbio-Pallavicini E, Porta C, Centurioni R, et al. Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma-exchange. Eur J Haematol 1994; 52:222-226
16. Moake JL, Rudy CK, Troll JH, et al. Therapy of chronic relapsing thrombotic thrombocytopenic purpura with prednisone and azathioprine. Am J Hematol 1985;20: 73-79
17. Fessler BJ. Thrombotic syndromes and autoimmune diseases. Rheum Dis Clin North Am 1997;23:461-479
18. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998;67:395-424
19. Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci USA 1990;87:6306-6310
20. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982;307:1432-1435
21. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001;98:1662-1666
22. Gerritsen HE, Robles R, Lämmle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 2001;98:1654-1661
23. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS-13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276:41059-41063
24. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001;413:488-494
25. Soejima K, Mimura N, Hirashima M, et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? J Biochem (Tokyo) 2001;130:475-480
26. Plaimauer B, Zimmermann K, Volkel D, et al. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS-13). Blood 2002;100:3626-3632
27. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997;89:3097-3103
28. Furlan M, Lämmle B. Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura. Baillieres Clin Haematol 1998; 11:509-514
29. Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-1584
30. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-1594
31. Furlan M, Robles R, Solenthaler M, Lämmle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 1998;91:2839-2846
32. Kolcame K, Matsumoto M, Soejima K, et al. Mutations and common polymorphisms in ADAMTS-13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A 2002;99:11902-11907
33. Schneppenheim R, Budde U, Oyen F, et al. Von Willebrand factor cleaving protease and ADAMTS-13 mutations in childhood TTP. Blood 2003;101:1845-1850
34. Antoine G, Zimmermann K, Plaimauer B, et al. ADAMTS-13 gene defects in two brothers with thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS-13. Br J Haematol 2003;120:821-824
35. Savasan S, Lee SK, Ginsburg D, Tsai HM. ADAMTS-13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal vWF cleaving protease activity. Blood 2003;101:4449-4451
36. Assink K, Schiprost R, Allford S, et al. Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency. Kidney Int 2003;63:1995-1999
37. Matsumoto M, Kolcame K, Soejima K, et al. Molecular characterization of ADAMTS-13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood 2004; 103:1305-1310
38. Veyradier A, Lavergne JM, Ribba AS, et al. The candidate ADAMTS-13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). J Thromb Haemost 2004;2:424-429
39. Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol 2001;14:437-454
40. Kremer-Hovinga JA, Studt JD, Lämmle B. The von Willebrand factor-cleaving protease (ADAMTS-13) and the diagnosis of thrombotic thrombocytopenic purpura (TTP). Pathophysiol Haemost Thromb 2004;33:417-421
41. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003;14:520-535
42. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology 1999;52:1701-1704
43. Berentsen S, Tjonnfjord GE, Brudevold R, et al. Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. Br J Haematol 2001;115:79-83
44. Specks U, Fervenza FC, McDonald TJ, Hogan MCE. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001;44:2836-2840
45. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98:952-957
46. Dimopoulos MA, Zervas C, Zomas A, et al. Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia. Clin Lymphoma 2002;3: 163-166
47. Mori A, Tamaru J, Sumi H, Kondo H. Beneficial effects of rituximab on primary cold agglutinin disease refractory to conventional therapy. Eur J Haematol 2002;68:243-246
48. Motto DG, Williams JA, Boxer LA. Rituximab for refractory childhood autoimmune hemolytic anemia. Isr Med Assoc J 2002;4:1006-1008
49. Perrotta S, Locatelli F, LaManna A, Cennamo L, DeStefano P, Nobili B. Anti-CD20 monoclonal antibody (rituximab) for life-threatening autoimmune haemolytic in a patient with systemic lupus erythematosus. BrJ Haematol 2002;116:465-467
50. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet 2002;360:923-924
51. Salopek TG, Logsetty S, Tredget EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol 2002;47:785-788
52. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101:3827-3834
53. Zaja F, Iacona I, Masolini P, et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 2002;87:189-195
54. Renaud S, Gregor M, Fuhr P, et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 2003;27:611-615
55. Trape G, Fianchi L, Lai M, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders. Haematologica 2003;88:223-225
56. Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 2003;101:3857-3861
57. Gutterman LA, Kloster B, Tsai HM. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis 2002;28:385-391
58. Chemnitz J, Draube A, Scheid C, et al. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. AmJ Hematol 2002;71:105-108
59. Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med 2003;138:105-108
60. Tsai HM, Shulman K. Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura. Eur J Haematol 2003;70:183-185
61. Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai HM. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol 2004;124:787-795
62. Salkh S, Husain A, Wan JY, Nguyen NP. Rituximab in patients with refractory thrombotic thrombocytopenic purpura. J Thromb Haemost 2004;2:834-836
63. Stein GY, Zeidman A, Fradin Z, Varon M, Cohen A, Mittelman M. Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide. Int J Hematol 2004;80:94-96
64. Ahmad A, Aggarwal A, Sharma D, et al. Rituximab for treatment of refractory thrombotic thrombocytopenic purpura (TTP). Am J Hematol 2004;77:171-176
65. Reddy PS, Deauna-Limayo D, Cook JD, et al. Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Ann Hematol 2005;84:232-235
66. Ruiz J, Koduri PR, Valdivieso M, Shah PC. Refractory post-pancreatitis thrombotic thrombocytopenic purpura: response to rituximab. Ann Hematol 2005;84:267-268
67. Koulova L, Alexandrescu D, Dutcher JP, O'Boyle KP, Eapen S, Wiernik PH. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases. Am J Hematol 2005;78:49-54
68. Galbusera M, Bresin E, Noris M, et al. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. Blood 2005;106:925-928
69. Fakhouri F, Vernant JP, Veyradier A, et al. Efficiency of curative and prophylactic treatment with Rituximab in ADAMTSlS-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005;106:1932-1937
70. Montecucco C, Caporali R. Hemocytopenias in antiphospholipid syndrome. In: Hughes GRV, Khamashta M, eds. Hughes Syndrome. London: Springler-Verlag; 2000:20-31
71. Durand JM, Lefevre P, Kaplanski G, Soubeyrand J. Thrombotic microangiopathy and the antiphospholipid antibody syndrome. J Rheumatol 1991;18:1916-1918
72. Musio F, Bohen EM, Yuan CM, et al. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin Arthritis Rheum 1998;28:1-19
73. Huang JJ, Chen MW, Sung JM, et al. Postpartum hemolytic uremic syndrome associated with antiphospholipid antibody. Nephrol Dial Transplant 1998;13:182-186
74. Falcini F, Taccetti G, Ermini M, et al. Catastrophic antiphospholipid antibody syndrome in pediatric systemic lupus erythematosus. J Rheumatol 1997;24:389-392
75. Vasoo S, Thumboo J, Fong KY. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: disease activity and the use of cytotoxic drugs. Lupus 2002;11:443-450
76. Devinsky O, Petito CK, Alonso DR. Clinical and neuropathological findings in systemic lupus erythematosus: the role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpura. Ann Neurol 1988;23:380-384
77. Porta C, Bobbio-Pallavicini E, Centurioni R, et al. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus. J Rheumatol 1993;20:1625-1626
78. Caramaschi P, Riccetti MM, Pasini AF, et al. Systemic lupus erythematosus and thrombotic thrombocytopenic purpura. Report of three cases and review of the literature. Lupus 1998;7:37-41
79. Jorfen M, Callejas JL, Formiga F, et al. Fulminant thrombotic thrombocytopenic purpura in systemic lupus erythematosus. Scand J Rheumatol 1998;27:76-77
80. Montecucco C, Longhi M, Caporali R, et al. Hematological abnormalities associated with anticardiolipin antibodies. Haematologica 1989;74:195-204
81. Espinosa G, Bucciarelli S, Cervera R, et al. Thrombotic microangiopathic haemolytic anemia and antiphospholipid antibodies. Ann Rheum Dis 2004;63:730-736
82. Ardues LG, Olavarria F, Elgueta M, et al. Anticardiolipin antibodies in classic pediatric hemolytic-uremic syndrome: a possible pathogenic role. Nephron 1998;78:278-283
83. Trent K, Neustater BR, Lottenberg R. Chronic thrombotic thrombocytopenic purpura and antiphospholipid antibodies: A report of two cases. Am J Hematol 1997;54:155-159
84. Knovich MA, Graver K, Matulis MD, et al. Simplified assay for VWF cleaving protease (ADAMTS-13) activity and inhibitor in plasma. Am J Hematol 2004;76:286-290
85. Mannucci PM, Vanoli M, Forza I, Canciani MT, Scorza R. Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue disease (systemic lupus erythematosus and systemic sclerosis). Haematologica 2003; 88:914-918
86. Rick ME, Austin H, Leitman SF, Krizek DM, Aronson DL. Clinical usefulness of a functional assay for the von Willebrand factor cleaving protease (ADAMTS-13) and its inhibitor in a patient with thrombotic thrombocytopenic purpura. Am J Hematol 2004;75:96-100
87. Bettendorf U, Potters R. Moschcowitz's syndrome following D-penicillamine medication. Med Welt 1975;26:291-295
88. Speth PA, Boerboons AM, Holdrinet RS, Van de Putte LB, Meyer JW. Thrombotic thrombocytopenic purpura associated with D-penicillamine treatment in rheumatoid arthritis. J Rheumatol 1982;9:812-813
89. Trice JM, Finals RS, Plitman GI. Thrombotic thrombocytopenic purpura during penicillamine therapy in rheumatoid arthritis. Arch Intern Med 1983;143:1487-1488
90. Ahmed F, Sumalnop V, Spain DM, Tobin MS. Thrombotic thrombocytopenic purpura during penicillamine therapy. Arch Intern Med 1978;138:1292-1293
91. Harrison EE, Hickman JW. Hemolytic anemia and thrombocytopenia associated with D-penicillamine therapy. South Med J 1975;68:113-115
92. Bobbio-Pallavicini E, Porta C, Fornasari PM, Viarengo GL, Ascari E. Thrombotic thrombocytopenic purpura (TTP): retrospective study on 84 patients and therapeutical prospects. Transfbs Sci 1992;13:39-44